Roberto Pili

  • 10704 Citations
  • 51 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Publications 1990 2019

2011
79 Citations (Scopus)

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination

Keizman, D., Huang, P., Eisenberger, M. A., Pili, R., Kim, J. J., Antonarakis, E. S., Hammers, H. & Carducci, M. A., Sep 2011, In : European Journal of Cancer. 47, 13, p. 1955-1961 7 p.

Research output: Contribution to journalArticle

Angiotensins
Renal Cell Carcinoma
Logistic Models
Survival
Angiotensin Receptor Antagonists
53 Citations (Scopus)

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Harrison, M. R., Hahn, N. M., Pili, R., Oh, W. K., Hammers, H., Sweeney, C., Kim, K., Perlman, S., Arnott, J., Sidor, C., Wilding, G. & Liu, G., Dec 2011, In : Investigational New Drugs. 29, 6, p. 1465-1474 10 p.

Research output: Contribution to journalArticle

Nanoparticles
Prostatic Neoplasms
Medical Futility
Gastrointestinal Hemorrhage
Hyponatremia
1 Citation (Scopus)

A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

Resta, L. P., Pili, R., Eisenberger, M. A., Spitz, A., King, S., Porter, J., Franke, A., Boinpally, R., Carducci, M. A. & Sweeney, C. J., Feb 2011, In : Cancer Chemotherapy and Pharmacology. 67, 2, p. 431-438 8 p.

Research output: Contribution to journalArticle

Mitoxantrone
Tumors
Neoplasms
Toxicity
Prednisone

Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects

George, S. & Pili, R., Oct 1 2011, Targeted Therapies for Renal Cell Carcinoma. Future Medicine Ltd., p. 121-125 5 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Diphosphonates
Renal Cell Carcinoma
Neoplasm Metastasis
Bone and Bones
Osteoclasts
14 Citations (Scopus)

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in MicroRNA expression

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R., Miles, K. M., Wang, D., Liu, S., Atadja, P., Carducci, M. A. & Pili, R., Nov 7 2011, In : PLoS One. 6, 11, e27178.

Research output: Contribution to journalArticle

Histone Deacetylases
Androgen Receptors
MicroRNAs
microRNA
histones
14 Citations (Scopus)

Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: Are surgical complications or disease related factors responsible?

O'Malley, R. L., Brewer, K. A., Hayn, M. H., Kim, H. L., Underwood, W., Pili, R. & Schwaab, T., Sep 2011, In : Urology. 78, 3, p. 595-600 6 p.

Research output: Contribution to journalArticle

Nephrectomy
Survival
Renal Cell Carcinoma
Therapeutics
Intraoperative Complications
34 Citations (Scopus)

Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells

Pettazzoni, P., Pizzimenti, S., Toaldo, C., Sotomayor, P., Tagliavacca, L., Liu, S., Wang, D., Minelli, R., Ellis, L., Atadja, P., Ciamporcero, E., Dianzani, M. U., Barrera, G. & Pili, R., Jan 15 2011, In : Free Radical Biology and Medicine. 50, 2, p. 313-322 10 p.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
Cell Cycle Checkpoints
Lipid Peroxidation
DNA Damage
Prostatic Neoplasms
64 Citations (Scopus)

Kidney cancer

Motzer, R. J., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Carducci, M. A., Chang, S. S., Choueiri, T. K., Hancock, S. L., Hudes, G. R., Jonasch, E., Josephson, D., Kuzel, T. M., Levine, E. G., Lin, D. W., Margolin, K. A., Michaelson, M. D., Olencki, T., Pili, R., Ratliff, T. W. & 7 others, Redman, B. G., Robertson, C. N., Ryan, C. J., Sheinfeld, J., Spiess, P. E., Wang, J. & Wilder, R. B., Sep 1 2011, In : JNCCN Journal of the National Comprehensive Cancer Network. 9, 9, p. 960-977 18 p.

Research output: Contribution to journalReview article

161 Citations (Scopus)

Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance

Gotink, K. J., Broxterman, H. J., Labots, M., De Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J., Jansen, G., Griffioen, A. W., Assaraf, Y. G., Pili, R., Peters, G. J. & Verheul, H. M. W., Dec 1 2011, In : Clinical Cancer Research. 17, 23, p. 7337-7346 10 p.

Research output: Contribution to journalArticle

Drug Resistance
sunitinib
Neoplasms
Cell Proliferation
Lysosomes
4 Citations (Scopus)

Mental disorders in obese patients with and without metabolic syndrome

Carpiniello, B., Pinna, F., Pili, R., Velluzzi, F. & Loviselli, A., Jan 1 2011, In : International Journal of Psychiatry in Medicine. 42, 4, p. 369-375 7 p.

Research output: Contribution to journalArticle

Mental Disorders
Abdominal Obesity
42 Citations (Scopus)

NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., Kumar, R., Margolin, K. A., Michaelson, M. D., Motzer, R. J., Pili, R., Roethke, S. & Srinivas, S., 2011, In : JNCCN Journal of the National Comprehensive Cancer Network. 9, SUPPL. 1

Research output: Contribution to journalArticle

Molecular Targeted Therapy
Advisory Committees
Renal Cell Carcinoma
Therapeutics
22 Citations (Scopus)

Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells

Pettazzoni, P., Ciamporcero, E., Medana, C., Pizzimenti, S., Dal Bello, F., Minero, V. G., Toaldo, C., Minelli, R., Uchida, K., Dianzani, M. U., Pili, R. & Barrera, G., Oct 15 2011, In : Free Radical Biology and Medicine. 51, 8, p. 1610-1618 9 p.

Research output: Contribution to journalArticle

Metabolism
Prostatic Neoplasms
Cells
4-hydroxy-2-nonenal
Detoxification
152 Citations (Scopus)

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

Pili, R., Hag̈gman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Bjor̈k, A., Nordle, O., Forsberg, G., Carducci, M. A. & Armstrong, A. J., Oct 20 2011, In : Journal of Clinical Oncology. 29, 30, p. 4022-4028 7 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Placebos
Castration
Disease-Free Survival
Neoplasm Metastasis
2 Citations (Scopus)

Provenge: Combating prostate cancer with a vengeance?

Schwaab, T. & Pili, R., Aug 2011, In : Expert Review of Vaccines. 10, 8, p. 1113-1114 2 p.

Research output: Contribution to journalEditorial

Cancer Vaccines
Tissue Extracts
Immunomodulation
Immunotherapy
Prostatic Neoplasms
25 Citations (Scopus)

Resistance to angiogenesis inhibitors in renal cell carcinoma

Tamaskar, I., Dhillon, J. & Pili, R., Feb 2011, In : Clinical Advances in Hematology and Oncology. 9, 2, p. 101-110 10 p.

Research output: Contribution to journalArticle

Angiogenesis Inhibitors
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Clinical Trials
Tumor Escape
22 Citations (Scopus)

Role of immunotherapy for renal cell cancer in 2011

George, S., Pili, R., Carducci, M. A. & Kim, J. J., Sep 1 2011, In : JNCCN Journal of the National Comprehensive Cancer Network. 9, 9, p. 1011-1018 8 p.

Research output: Contribution to journalReview article

Renal Cell Carcinoma
Immunotherapy
Interferons
Interleukin-2
Sirolimus
2010
55 Citations (Scopus)

Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies

Ellis, L. & Pili, R., 2010, In : Pharmaceuticals. 3, 8, p. 2441-2469 29 p.

Research output: Contribution to journalReview article

Histone Deacetylase Inhibitors
Hematologic Neoplasms
Histone Deacetylases
Autophagy
Apoptosis

Is this a true renaissance for the treatment of prostate cancer?

Pili, R., Dec 2010, In : Oncology (Williston Park, N.Y.). 24, 14, p. 1327-1328 2 p.

Research output: Contribution to journalComment/debate

Androgen Antagonists
Tissue Extracts
Antineoplastic Agents
Prostatic Neoplasms
Renaissance

Is this a true renaissance for the treatment of prostate cancer?

Pili, R., Dec 2010, In : Oncology. 24, 14

Research output: Contribution to journalComment/debate

Prostatic Neoplasms
Renaissance
29 Citations (Scopus)

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I/II double-blinded, randomized study

Keizman, D., Zahurak, M., Sinibaldi, V., Carducci, M., Denmeade, S., Drake, C., Pili, R., Antonarakis, E. S., Hudock, S. & Eisenberger, M., Nov 1 2010, In : Clinical Cancer Research. 16, 21, p. 5269-5276 8 p.

Research output: Contribution to journalArticle

Prostate-Specific Antigen
Prostatic Neoplasms
Neutropenia
Population
Androgens
32 Citations (Scopus)

Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: An illustration with the Supportive Care Needs Survey and the QLQ-C30

Snyder, C. F., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Aug 2010, In : Quality of Life Research. 19, 6, p. 837-845 9 p.

Research output: Contribution to journalArticle

Needs Assessment
ROC Curve
Area Under Curve
Aptitude
Fatigue
28 Citations (Scopus)

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

Koskimaki, J. E., Karagiannis, E. D., Tang, B. C., Hammers, H., Watkins, D. N., Pili, R. & Popel, A. S., Feb 1 2010, In : BMC Cancer. 10, 29.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Heterografts
Collagen
Peptides
Growth
45 Citations (Scopus)

Phase II study on the addition of ASA404 (vadimezan; 5,6- dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

Pili, R., Rosenthal, M. A., Mainwaring, P. N., Van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S. & Clingan, P., May 15 2010, In : Clinical Cancer Research. 16, 10, p. 2906-2914 9 p.

Research output: Contribution to journalArticle

vadimezan
docetaxel
Castration
Prostatic Neoplasms
Prostate-Specific Antigen
122 Citations (Scopus)

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study

Hammers, H. J., Verheul, H. M., Salumbides, B., Sharma, R., Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S., Dykema, K., Furge, K., Teh, B. T., Netto, G. & Pili, R., Jun 2010, In : Molecular Cancer Therapeutics. 9, 6, p. 1525-1535 11 p.

Research output: Contribution to journalArticle

Epithelial-Mesenchymal Transition
Renal Cell Carcinoma
Heterografts
Pericytes
Neoplasms
30 Citations (Scopus)

The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell Renal Cell Carcinoma

Verheul, H. M. W., van Erp, K., Homs, M. Y. V., Yoon, G. S., van Der Groep, P., Rogers, C., Hansel, D. E., Netto, G. J. & Pili, R., Mar 2010, In : Urology. 75, 3, p. 608-614 7 p.

Research output: Contribution to journalArticle

Blood Coagulation Factors
Fibrin
Renal Cell Carcinoma
Fibrinogen
Vascular Endothelial Growth Factor A
2009
30 Citations (Scopus)

Concordance of cancer patients' function, symptoms, and supportive care needs

Snyder, C. F., Garrett-Mayer, E., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Oct 2009, In : Quality of Life Research. 18, 8, p. 991-998 8 p.

Research output: Contribution to journalArticle

Neoplasms
Observational Studies
Cross-Sectional Studies
144 Citations (Scopus)

Kidney cancer

Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., Hudes, G. R., Jonasch, E., Kessinger, A., Kuzel, T. M., Lange, P. H., Levine, E. G., Margolin, K. A., Michaelson, M. D., Olencki, T., Pili, R. & 5 others, Redman, B. G., Robertson, C. N., Schwartz, L. H., Sheinfeld, J. & Wang, J., Jun 2009, In : JNCCN Journal of the National Comprehensive Cancer Network. 7, 6, p. 618-630 13 p.

Research output: Contribution to journalReview article

Kidney Neoplasms
Renal Cell Carcinoma
Cell- and Tissue-Based Therapy
Protein-Tyrosine Kinases
Interferons
1654 Citations (Scopus)

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., Garcia-del-Muro, X., Sosman, J. A., Solska, E., Wilding, G., Thompson, J. A., Kim, S. T., Chen, I., Huang, X. & Figlin, R. A., Aug 1 2009, In : Journal of Clinical Oncology. 27, 22, p. 3584-3590 7 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interferon-alpha
Survival
Disease-Free Survival
Hand-Foot Syndrome
3 Citations (Scopus)

Pre-clinical models of renal carcinoma and their utility in drug development

Salumbides, B. C., Lehet, K. M., Ndikuyeze, G. & Pili, R., 2009, In : Current Protocols in Pharmacology. SUPPL.47

Research output: Contribution to journalReview article

Kidney Neoplasms
Carcinoma
Kidney
Renal Cell Carcinoma
Pharmaceutical Preparations
2 Citations (Scopus)
Histone Deacetylase Inhibitors
Histone Deacetylases
Kidney Neoplasms
Enzyme Inhibitors
Acetylation
168 Citations (Scopus)

Targeting tumor angiogenesis with histone deacetylase inhibitors

Ellis, L., Hammers, H. & Pili, R., Aug 8 2009, In : Cancer Letters. 280, 2, p. 145-153 9 p.

Research output: Contribution to journalShort survey

Histone Deacetylase Inhibitors
Hypoxia-Inducible Factor 1
Histone Deacetylases
Neoplasms
Vascular Endothelial Growth Factor A
80 Citations (Scopus)

Testicular cancer

Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., Hudes, G. R., Jonasch, E., Kessinger, A., Kuzel, T. M., Lange, P. H., Levine, E. G., Margolin, K. A., Michaelson, M. D., Olencki, T., Pili, R. & 5 others, Redman, B. G., Robertson, C. N., Schwartz, L. H., Sheinfeld, J. & Wang, J., Jun 2009, In : JNCCN Journal of the National Comprehensive Cancer Network. 7, 6, p. 672-693 22 p.

Research output: Contribution to journalReview article

Testicular Neoplasms
Germ Cell and Embryonal Neoplasms
Neoplasms
Seminoma
Carboplatin
18 Citations (Scopus)

Update on novel agents in renal cell carcinoma

Tamaskar, I. & Pili, R., Dec 2009, In : Expert Review of Anticancer Therapy. 9, 12, p. 1817-1827 11 p.

Research output: Contribution to journalReview article

Renal Cell Carcinoma
Therapeutics
Standard of Care
Natural History
Drug Resistance
35 Citations (Scopus)

VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo

Kolmakova, A., Rajesh, M., Zang, D., Pili, R. & Chatterjee, S., Jul 2009, In : Glycoconjugate Journal. 26, 5, p. 547-558 12 p.

Research output: Contribution to journalArticle

Endothelial cells
Cell Adhesion Molecules
Vascular Endothelial Growth Factor A
Endothelial Cells
CD31 Antigens
96 Citations (Scopus)

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study

Vaughn, D. J., Srinivas, S., Stadler, W. M., Pili, R., Petrylak, D., Sternberg, C. N., Smith, D. C., Ringuette, S., De Wit, E., Pautret, V. & George, C., Sep 15 2009, In : Cancer. 115, 18, p. 4110-4117 8 p.

Research output: Contribution to journalArticle

Platinum
Carcinoma
Advisory Committees
Disease Progression
Karnofsky Performance Status
86 Citations (Scopus)

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium

Bradley, D., Rathkopf, D., Dunn, R., Stadler, W. M., Liu, G., Smith, D. C., Pili, R., Zwiebel, J., Scher, H. & Hussain, M., Jan 12 2009, In : Cancer. 115, 23, p. 5541-5549 9 p.

Research output: Contribution to journalArticle

National Cancer Institute (U.S.)
Interleukin-6
Prostatic Neoplasms
Clinical Trials
Drug Therapy
2008
132 Citations (Scopus)

A Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., Pili, R., Carducci, M. A., Erlichman, C. & Liu, G., Dec 1 2008, In : Clinical Cancer Research. 14, 23, p. 7940-7946 7 p.

Research output: Contribution to journalArticle

tanespimycin
Prostatic Neoplasms
Prostate-Specific Antigen
Hormones
Fatigue
94 Citations (Scopus)

Combination strategy targeting the hypoxia inducible factor-1 α with mammalian target of rapamycin and histone deacetylase inhibitors

Verheul, H. M. W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P. & Pili, R., Jun 1 2008, In : Clinical Cancer Research. 14, 11, p. 3589-3597 9 p.

Research output: Contribution to journalArticle

Hypoxia-Inducible Factor 1
Histone Deacetylase Inhibitors
Sirolimus
Human Umbilical Vein Endothelial Cells
Western Blotting
403 Citations (Scopus)

Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O. & Semenza, G. L., Dec 16 2008, In : Proceedings of the National Academy of Sciences of the United States of America. 105, 50, p. 19579-19586 8 p.

Research output: Contribution to journalArticle

Hypoxia-Inducible Factor 1
Cardiac Glycosides
Digoxin
Growth
Neoplasms
29 Citations (Scopus)

Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration

Nguyen, Q. D., Shah, S. M., Hafiz, G., Do, D. V., Haller, J. A., Pili, R., Zimmer-Galler, I. E., Janjua, K., Symons, R. C. A. & Campochiaro, P. A., Feb 2008, In : American Journal of Ophthalmology. 145, 2

Research output: Contribution to journalArticle

Choroidal Neovascularization
Macular Degeneration
Fluorescein
Diabetic Retinopathy
Intravenous Infusions
20 Citations (Scopus)

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

Rathkopf, D., Carducci, M. A., Morris, M. J., Slovin, S. F., Eisenberger, M. A., Pili, R., Denmeade, S. R., Kelsen, M., Curley, T., Halter, M., Collins, C., Fleisher, M., Heller, G., Baker, S. D. & Scher, H. I., 2008, In : Journal of Clinical Oncology. 26, 18, p. 2959-2965 7 p.

Research output: Contribution to journalArticle

docetaxel
Androgens
Prostatic Neoplasms
Testosterone
Leuprolide
104 Citations (Scopus)

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

Siu, L. L., Pili, R., Duran, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., Li, Z., Kalita, A. M., Laille, E. J., Besterman, J. M., Martell, R. E. & Carducci, M. A., 2008, In : Journal of Clinical Oncology. 26, 12, p. 1940-1947 8 p.

Research output: Contribution to journalArticle

Histones
Neoplasms
Pharmacokinetics
Acetylation
Beverages
22 Citations (Scopus)

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acidin cancer patients

Li, J., Jameson, M. B., Baguley, B. C., Pili, R. & Baker, S. D., Apr 1 2008, In : Clinical Cancer Research. 14, 7, p. 2102-2110 9 p.

Research output: Contribution to journalArticle

Acetic Acid
Blood Vessels
Pharmacokinetics
Population
Neoplasms
11 Citations (Scopus)

Posttranscription regulation of prostate cancer growth

Shen, L. & Pili, R., Jan 2008, In : Cancer journal (Sudbury, Mass.). 14, 1, p. 46-53 8 p.

Research output: Contribution to journalReview article

Prostatic Neoplasms
Growth
Proteins
Histone Deacetylase Inhibitors
Androgen Receptors
22 Citations (Scopus)

Reproducibility of tumor blood flow quantification with15O-water PET

Lodge, M. A., Jacene, H. A., Pili, R. & Wahl, R. L., Oct 1 2008, In : Journal of Nuclear Medicine. 49, 10, p. 1620-1627 8 p.

Research output: Contribution to journalArticle

Water
Neoplasms
Isotopes
Half-Life
Pharmaceutical Preparations
40 Citations (Scopus)

Symptoms, supportive care needs, and function in cancer patients: How are they related?

Snyder, C. F., Garrett-Mayer, E., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Jun 2008, In : Quality of Life Research. 17, 5, p. 665-677 13 p.

Research output: Contribution to journalArticle

Health Information Systems
Appetite
Psychology
Cognition
Fatigue
2007
11 Citations (Scopus)

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma

Zhao, M., Rudek, M. A., Mnasakanyan, A., Hartke, C., Pili, R. & Baker, S. D., Jan 17 2007, In : Journal of Pharmaceutical and Biomedical Analysis. 43, 2, p. 784-787 4 p.

Research output: Contribution to journalArticle

Plasma (human)
formic acid
Liquid chromatography
Tandem Mass Spectrometry
Liquid Chromatography
48 Citations (Scopus)

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

Qian, D. Z., Wei, Y. F., Wang, X., Kato, Y., Cheng, L. & Pili, R., Aug 1 2007, In : Prostate. 67, 11, p. 1182-1193 12 p.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
Prostatic Neoplasms
Acetylation
Growth
Histones
43 Citations (Scopus)

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

Kato, Y., Salumbides, B. C., Wang, X. F., Qian, D. Z., Williams, S., Wei, Y., Sanni, T. B., Atadja, P. & Pili, R., Jan 2007, In : Molecular Cancer Therapeutics. 6, 1, p. 70-81 12 p.

Research output: Contribution to journalArticle

NSC 153174
Isotretinoin
Histone Deacetylase Inhibitors
Melanoma
Tretinoin
34 Citations (Scopus)

Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidence of Biochemical Relapse After Definitive Radical Retropubic Prostatectomy or Radiotherapy

Bajaj, G. K., Zhang, Z., Garrett-Mayer, E., Drew, R., Sinibaldi, V., Pili, R., Denmeade, S. R., Carducci, M. A., Eisenberger, M. A. & DeWeese, T. L., Mar 2007, In : Urology. 69, 3, p. 526-531 6 p.

Research output: Contribution to journalArticle

Prostatectomy
Prostatic Neoplasms
Radiotherapy
Recurrence
Prostate-Specific Antigen